Reports of the death of dental cavities are greatly exaggerated
Efforts to prevent dental cavities by replacing native oral bacteria with engineered strains, such as the Lumina/BCS3-L1 product, are provoking sharp debate over safety, effectiveness, and regulation. Commenters question whether targeting Streptococcus mutans can meaningfully reduce caries given the complexity of the oral microbiome, and highlight risks like hard‑to‑reverse colonization, gene transfer that could make the bacteria pathogenic, and ecosystem disruption. Others argue that even partial cavity reduction could be valuable, blame stringent FDA trial requirements for stalling innovation, and contrast such biotech approaches with established measures like fluoride, diet, and conventional oral hygiene.
Role of S. mutans and citation quality
- Several comments dissect the article’s citation trail about S. mutans being “<2% of bacteria that cause caries.”
- They note a slide from “implicated in caries” → “cause caries” → mere prevalence in plaque/lesions.
- This is used to argue the article overstates how little S. mutans matters, even though other acid-producing species clearly play important roles.
Lumina/BCS3-L1: efficacy vs risk
- Some see Lumina as potentially valuable even if it only partially reduces cavities; non‑perfect benefit could still be meaningful at scale.
- Others argue the article ignores partial benefit and is too dismissive, focusing on “not a cure” rather than “how much reduction.”
- Major safety concerns raised from the thread and article:
- Engineered strain can form persistent biofilms and may be hard to eradicate.
- Potential to acquire pathogenic genes laterally and become harmful.
- Possible suppression of beneficial oral microbiota.
- No clear “kill switch” and unknown long‑term systemic effects (e.g., if colonizing the gut, theoretical links like auto‑brewery syndrome).
- Critics of Lumina stress that even its intended mechanism may not substantially reduce caries if many other bacteria fill the same niche.
Regulation, FDA, and Prospera
- One camp blames FDA requirements (especially quarantine and containment) for making human trials effectively impossible, thus stalling innovation.
- Others respond that, because the bacteria could spread beyond volunteers, strict controls are appropriate—analogous to containing other transmissible agents.
- Debate over whether regulators are too biased toward avoiding visible harm vs enabling progress.
- Some point out Lumina is now being sold in a lightly regulated jurisdiction (Próspera), which others see as a red flag rather than a feature.
Alternatives: fluoride, probiotics, hygiene, and folk methods
- Multiple comments emphasize that conventional oral hygiene (brushing with fluoride toothpaste, flossing/interdental cleaning, diet control) remains the best‑supported strategy.
- There’s discussion of:
- Fluoride’s effectiveness and concerns about water fluoridation vs topical use.
- Alternative products (e.g., hydroxyapatite/Novamin toothpastes, S. salivarius M18 probiotics) with varying levels of supporting evidence.
- Oil pulling and vitamin K2, generally viewed skeptically or as anecdotal.
- Flossing evidence: some note weak high‑quality data; others cite institutional recommendations.
Genetics, lifestyle, and variability
- Many anecdotes highlight large individual differences in cavity susceptibility despite similar hygiene and diet, suggesting genetics, microbiome composition, early‑life conditions, and other factors play substantial roles beyond behavior alone.